Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes

References

• Vincent A, McConville J, Farrugia ME, et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003;998:324-35
   PubMed Web of Science ®Google Scholar
• Diaz-Manera J, Rojas-Garcia R, Gallardo E, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan’s syndrome. Nat Clin Pract Neurol 2007;3(7):410-05
   Google Scholar
• Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 2014;52:139-45
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Dervenoulas G, Kokotis P, et al. Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms. J Neurol Sci 2014; doi: 10.1016/j.jns.2014.09.013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2013;76:23-2017
   Google Scholar
• Zinman LH, Sutton D, Nwe P, et al. A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfus Apher Sci 2005;33(3):317-24
   PubMed Web of Science ®Google Scholar
• Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68(11):837-41
   PubMed Web of Science ®Google Scholar
• Jensen P, Bril V. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscul Dis 2008;9(3):352-5
   PubMedGoogle Scholar
• Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17(7):893-902
   PubMed Web of Science ®Google Scholar
• Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012;78(13):1009-15
   PubMed Web of Science ®Google Scholar
• Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014;175(3):408-18
   PubMed Web of Science ®Google Scholar
• Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008;29(12):608-15
   PubMed Web of Science ®Google Scholar
• Gajdos P, Outin H, Elkharrat D, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1(8373):406-7
   PubMed Web of Science ®Google Scholar
• Fateh-Moghadam A, Wick M, Besinger U, Geursen RG. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1(8381):848-9
   PubMed Web of Science ®Google Scholar
• Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971;6(8):497-537
   Google Scholar
• Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012;12:CD002277
   PubMedGoogle Scholar
• Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005;62(11):1689-93
   PubMedGoogle Scholar
• Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41(6):789-96
   PubMed Web of Science ®Google Scholar
• Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25(12):967-73
   PubMed Web of Science ®Google Scholar
• Hellmann MA, Mosberg-Galili R, Lotan I, Steiner I. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol Sci 2014;338(1-2):39-42
   PubMed Web of Science ®Google Scholar
• Liew WKM, Powell CA, Sloan SR, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol 2014;71(5):575-80
   PubMed Web of Science ®Google Scholar
• Eienbröker C, Seitz F, Spengler A, et al. IVIg maintenance treatment in myasthenia gravis-a RCT sample size simulation. Muscle Nerve 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sorgun MH, Sener HO, Yucesan C, Yucemen N. Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis. Neurol Sci 2014;35(6):891-6
   PubMed Web of Science ®Google Scholar
• Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-51
   PubMed Web of Science ®Google Scholar
• Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769-72
   PubMed Web of Science ®Google Scholar
• Sharshar T, Chevret S, Mazighi M, et al. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 2000;247(4):286-90
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Simel DL, Bosworth H, et al. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 1970;64:11-1968
   Google Scholar
• Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 2000;70(1):327-34
   PubMed Web of Science ®Google Scholar
• Katzberg HD, Barnett C, Merkies IS, Bril V. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve 2014;49(5):661-5
   PubMed Web of Science ®Google Scholar
• Barnett C, Katzberg H, Nabavi M, Bril V. The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers. J Clin Neuromuscul Dis 2012;13(4):201-5
   PubMedGoogle Scholar
• Burns TM, Conaway MR, Cutter GR, Sanders DB. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008;38(2):957-63
   PubMed Web of Science ®Google Scholar
• Katzberg HD, Barnett C, Bril V. Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle Nerve 2012;45(5):648-52
   PubMed Web of Science ®Google Scholar
• Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci 2003;998:440-4
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Barohn RJ, Sanders DB, McDermott MP. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. Muscle Nerve 2008;38(5):1429-33
   PubMed Web of Science ®Google Scholar
• Barnett TC, Bril V, Davis AM. Performance of individual items of the quantitative myasthenia gravis score. Neuromuscul Disord 2013;23(5):413-17
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway MR, Cutter GR, Sanders DB. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008;38(6):1553-62
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology 2010;74(18):1434-40
   PubMed Web of Science ®Google Scholar
• Benatar M, Sanders DB, Burns TM, et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 2012;45(6):909-17
   PubMed Web of Science ®Google Scholar
• Burns TM. The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann N Y Acad Sci 2012;1274:99-106
   PubMed Web of Science ®Google Scholar
• Barnett C, Merkie I, Katzberg H, Bril V. Comparison of the quantitative myasthenia gravis score and the myasthenia gravis composite scale using Rasch analysis. Muscle Nerve 2013;48:S1: S1
   PubMedGoogle Scholar
• Barnett C, Bril V, Kapral M, et al. A conceptual framework for evaluating impairments in myasthenia gravis. PLoS One 2014;9(5):e98089
   PubMed Web of Science ®Google Scholar
• Barnett C, Wilson G, Barth D, et al. Changes in MG-QOL with IVIG or plasmapheresis in patients with myasthenia gravis. J Neurol Neursurg Psychiatry 2013;84(1):94-7
   PubMed Web of Science ®Google Scholar
• Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2006;2:CD002277
   Google Scholar
• Sanders DB. Clinical impact of single-fiber electromyography. Muscle Nerve Suppl 2002;11(S11):S15-20
   PubMedGoogle Scholar
• Katzberg H, Bril V. A comparison of electrodiagnostic tests in ocular myasthenia gravis. J Clin Neuromusc Dis 2005;6:109-13
   PubMedGoogle Scholar
• Zinman L, Baryshnik D, Bril V. Surrogate therapeutic outcome measures in patients with myasthenia gravis. Muscle Nerve 2008;37(2):172-6
   PubMed Web of Science ®Google Scholar
• Gilchrist JM, Massey JM, Sanders DB. Single fiber EMG and repetitive stimulation of the same muscle in myasthenia gravis. Muscle Nerve 1994;17(2):171-5
   PubMed Web of Science ®Google Scholar
• Sanders DB, Burns TM, Cutter GR, et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 2014;49(4):483-6
   PubMed Web of Science ®Google Scholar
• Kuks JB, Limburg PC, Horst G, Oosterhuis HJ. Antibodies to skeletal muscle in myasthenia gravis. Part 2. Prevalence in non-thymoma patients. J Neurol Sci 1993;120(1):78-81
   PubMed Web of Science ®Google Scholar